Bazarko Daniel 4
4 · ALEXION PHARMACEUTICALS, INC. · Filed Dec 21, 2020
Insider Transaction Report
Form 4
Bazarko Daniel
SVP, Controller, CAO
Transactions
- Exercise/Conversion
Common Stock, par value $.0001 per share
2020-12-17$97.58/sh+13,066$1,274,980→ 43,949 total - Exercise/Conversion
Common Stock, par value $.0001 per share
2020-12-17$140.16/sh+11,000$1,541,760→ 54,949 total - Sale
Common Stock, par value $.0001 per share
2020-12-17$157.59/sh−9,900$1,560,141→ 45,049 total - Sale
Common Stock, par value $.0001 per share
2020-12-17$157.76/sh−13,066$2,061,292→ 31,983 total - Sale
Common Stock, par value $.0001 per share
2020-12-17$158.00/sh−1,100$173,800→ 30,883 total - Exercise/Conversion
Common Stock
2020-12-17−13,066→ 0 totalExercise: $97.58Exp: 2023-06-01→ Common Stock, par value $.0001 per share (13,066 underlying) - Exercise/Conversion
Common Stock
2020-12-17−11,000→ 0 totalExercise: $140.16Exp: 2026-02-28→ Common Stock, par value $.0001 per share (11,000 underlying)
Footnotes (3)
- [F1]This transaction was executed in multiple trades through a broker-dealer at prices ranging from $157.75 - $157.79. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
- [F2]Beginning June 1, 2013, options became exercisable 25% after one year and 1/16 every three months thereafter until fully vested over 4 years.
- [F3]Beginning February 26, 2016, options became exercisable 25% after one year and 1/16 every three months thereafter until fully vested over 4 years.